Skip to Content Facebook Feature Image

NSFOCUS Receives Frost & Sullivan's 2025 Asia-Pacific Competitive Strategy Leadership Award for Excellence in Anti-DDoS Protection

Business

NSFOCUS Receives Frost & Sullivan's 2025 Asia-Pacific Competitive Strategy Leadership Award for Excellence in Anti-DDoS Protection
Business

Business

NSFOCUS Receives Frost & Sullivan's 2025 Asia-Pacific Competitive Strategy Leadership Award for Excellence in Anti-DDoS Protection

2025-06-03 17:58 Last Updated At:18:15

The company is being recognized for its technological innovation, customer-centric approach, and market-leading on-premises DDoS defense solutions across the Asia-Pacific cybersecurity landscape.

SAN ANTONIO, June 3, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that NSFOCUS has been recognized with the 2025 Asia-Pacific Competitive Strategy Leadership Award in the Anti-DDoS industry for its outstanding achievements in delivering cutting-edge, scalable, and cost-effective DDoS protection solutions. This recognition highlights NSFOCUS's continued leadership in driving intelligent innovation, enhancing customer experience, and solidifying its competitive positioning in an increasingly complex threat environment.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. NSFOCUS excelled in both, demonstrating an exceptional ability to translate strategic foresight into scalable, impactful action. "Driven by a steadfast focus on customer success, NSFOCUS consistently enhances its solutions to deliver exceptional experiences across all touchpoints. Its flexible pricing models cater to businesses of every scale, while dedicated product teams continually refine both hardware and virtual offerings to ensure high performance at competitive costs. With strategically located scrubbing centers across APAC, NSFOCUS boosts mitigation capacity and reduces latency and downtime for WAAP services, supporting seamless and uninterrupted operations," said Vivien Pua, senior industry analyst, cybersecurity, at Frost & Sullivan.

Guided by a long-term strategy centered on innovation, regional partnerships, and customer empowerment, NSFOCUS has displayed remarkable agility in addressing shifting cyberthreats while elevating value for enterprises of all sizes. Through sustained investment in next-generation threat detection and mitigation capabilities, the company has successfully scaled its presence across APAC, enabling faster and more reliable protection in diverse, high-risk network environments.

Innovation remains a central tenet of NSFOCUS's approach. Its flagship On-Premises DDoS Defenses suite—including the Network Traffic Analyzer (NTA), Anti-DDoS System (ADS), and ADS Manager (ADS-M)—empowers organizations to swiftly identify, neutralize, and monitor the most sophisticated volumetric and application-layer attacks.

NSFOCUS's commitment to delivering a superior customer experience further distinguishes it in the market. By integrating AI-driven threat detection, automation, and real-time reporting through systems like ADS-M and the Active Defense Business Operating System (ADBOS), the company simplifies network defense operations while enhancing accuracy and efficiency. Its customer-centric portal design and flexible deployment models reflect a deep understanding of the operational and economic realities faced by enterprises today.

Frost & Sullivan commends NSFOCUS for setting a benchmark in strategic execution and market responsiveness. The company's relentless focus on innovation, client success, and regional collaboration exemplifies best-in-class leadership in cybersecurity. With a robust pipeline of intelligent technologies and a culture rooted in proactive adaptation, NSFOCUS continues to redefine anti-DDoS protection in Asia-Pacific.

Each year, Frost & Sullivan presents the Competitive Strategy Leadership Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Tarini Singh
E: Tarini.Singh@frost.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

NSFOCUS Receives Frost & Sullivan's 2025 Asia-Pacific Competitive Strategy Leadership Award for Excellence in Anti-DDoS Protection

NSFOCUS Receives Frost & Sullivan's 2025 Asia-Pacific Competitive Strategy Leadership Award for Excellence in Anti-DDoS Protection

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Recommended Articles